Company news

Syndax Pharmaceuticals, Inc. news in 2022

Syndax Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

December 13, 2022

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

December 9, 2022

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

December 7, 2022

Syndax Announces Proposed $150 million Public Offering of Common Stock

December 5, 2022

Syndax Announces Pricing of $150 Million Public Offering of Common Stock

December 5, 2022

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

December 4, 2022

Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia

December 4, 2022

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

December 1, 2022

Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference

November 20, 2022

Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

November 2, 2022

Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

November 2, 2022

Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

October 26, 2022

Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

August 7, 2022

Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022

August 1, 2022

Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer

June 12, 2022

Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day

May 10, 2022

Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update

May 8, 2022

Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022

May 1, 2022

Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update

February 28, 2022

Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer

February 28, 2022

Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022

February 21, 2022

Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development

February 2, 2022

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

January 19, 2022

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 6, 2022

Calls in 2022

Decks in 2022